* EMA RECOMMENDS APPROVAL OF COMIRNATY AND SPIKEVAX COVID-19 VACCINES FOR CHILDREN FROM 6 MONTHS OF AGE: 19/10/2022

* CHMP HAS RECOMMENDED EXTENDING THE USE OF COMIRNATY AND SPIKEVAX TARGETING THE ORIGINAL STRAIN OF SARS-COV-2. * CHMP RECOMMENDED INCLUDING USE IN CHILDREN AGED 6 MONTHS TO 4 YEARS FOR COMIRNATY AND USE IN CHILDREN AGED 6 MONTHS TO 5 YEARS FOR SPIKEVAX

* IN CHILDREN FROM 6 MONTHS TO 4 YEARS OF AGE, COMIRNATY CAN BE GIVEN AS PRIMARY VACCINATION CONSISTING OF THREE DOSES * IN CHILDREN FROM 6 MONTHS TO 5 YEARS OF AGE, SPIKEVAX CAN BE GIVEN AS PRIMARY VACCINATION CONSISTING OF TWO DOSES

* CHMP CONCLUDED THAT BENEFITS OF COMIRNATY AND SPIKEVAX IN CHILDREN AGED FROM 6 MONTHS TO 4 AND 5 YEARS, RESPECTIVELY, OUTWEIGH RISKS * COMPARED TO THE DOSES FOR ALREADY AUTHORISED AGE GROUPS, THE DOSES OF BOTH VACCINES IN THE NEW YOUNGER AGE GROUPS WILL BE LOWER Source text for Eikon: Further company coverage: [ ]

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)